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Abstract
Earlier studies have demonstrated an over-expression of 9-O-acetylated sialoglycoconjugates
(9-OAcSGs) on lymphoblasts, concomitant with high titers of anti-9-OAcSGs in childhood acute
lymphoblastic leukemia (ALL). The present study was aimed to evaluate whether this high induction
of anti-9-OAcSGs at disease presentation contributes toward immune surveillance. Accordingly, anti-
9-OAcSGs were affinity purified from sera of ALL patients and normal individuals, and their specificity
toward the glycotope having terminal 9-O-acetylated sialic acid-linked subterminal N-acetyl
galactosamine (GalNAc) in a2–6 manner (9-OAcSAa2–6GalNAc) was established by hemagglutination
assay, flow cytometry and confocal microscopy. Subclass distribution of anti-9-OAcSGs revealed
a predominance of IgG2 in ALL. Analysis of glycosylation of anti-9-OAcSGs purified from sera of ALL
patients (IgGALL) and normal individuals (IgGN) by digoxigenin glycan enzyme assay, fluorimetric
estimation, gas–liquid chromatography and lectin-binding assays demonstrated that disease-specific
antibodies differ in content and nature as compared with normal controls. Enhanced amount of
9-OAcSA-specific IgG2 induced in ALL was unable to trigger activation of FccR, the complement
cascade and cell-mediated cytotoxicity, although its glycotope-binding ability remains unaffected.
Interestingly, only IgG1N emerged as the potent mediator of cell-mediated cytotoxicity, complement
fixation and activator of effector cells through FccR. In ALL, the observed subclass switching of
anti-9-OAcSGs to IgG2, alteration in their glycosylation profile along with impairment of a few
Fc-glycosylation-sensitive effector functions hints toward a disbalanced homeostasis, thereby
evading the host defense. These findings justify further evaluation of the mechanism for functional
unresponsiveness of antibodies and production of 9-OAcSA-specific chimeric antibodies with normal
Fc domain for therapeutic applications.
Introduction
Acute lymphoblastic leukemia (ALL) is a malignant trans-
formation of lymphoblasts and represents the single most
common type of cancer in the pediatric population (1). The
cure rates have increased to 80% due to improved diagnos-
tics, identification of risk factors and intensification of risk-
directed therapy. Although current treatment protocols induce
complete remission in >80% of children, a 20% risk of relapse
remains as patients in remission may harbor minimal residual
disease, not identifiable by routine cytomorphology (2).
Sialic acids (originally abbreviated as Neu5Ac), a family of
acidic nine-carbon sugars, are typically located at the terminal
positions of glycoconjugates of cell membranes and play
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a significant role in the mediation of many biological phenom-
ena involving cell–cell interactions either by reacting with
specific surface receptors or via masking of carbohydrate
recognition sites (3, 4). Among the diverse multitude of varia-
tions of Neu5Ac, the most frequently occurring modification
is O-acetylation at positions C-7, -8 and -9 to form N-acetyl-7,
-8, -9-O-acetyl neuraminic acid, respectively, thus generating
a family of O-acetylated sialoglycoconjugates (O-AcSGs) (5).
However, as O-acetyl esters from C-7 and C-8 positions
spontaneously migrate to C-9 position, even under physio-
logical conditions, the O-acetylation at C-9 position ½9-O-
acetylated sialic acid (9-OAcSA) is considered as the
commonest biologically occurring modification (6, 7).
The binding specificity of Achatinin-H, a 9-OAcSAa2–
6GalNAc-binding lectin, purified from the hemolymph of the
African giant land snail, Achatina fulica (8–11), allowed us to
identify an enhanced expression of five molecules having
terminal 9-OAcSA corresponding to 36, 90, 120, 135 and
144 kDa on PBMC of ALL patients; a basal level of expression
of only two molecules having terminal 9-OAcSA (36 and
144 kDa) was identified on PBMC from normal individuals (3,
7, 12, 13). An increased antibody (anti-9-OAcSGs) production
against these glycoproteins in these children confirmed its
immunogenicity (14–16). Importantly, no cross-reactivity was
observed with patients having other hematological disorders
(3, 12–16). At disease presentation, high titers of immune-
complexed 9-OAcSGs were observed in these patients’ sera
(17). These circulating anti-9-OAcSGs (free as well as immune
complexed) have been successfully utilized for diagnosis and
monitoring of the disease status (13–17).
A central question in cancer immunology is whether recogni-
tion of tumor antigens by the immune system initiates activation
(i.e. surveillance) or functional unresponsiveness. Paradoxic-
ally, while strong evidence exists that specific immune-
surveillance systems operate at early stages of tumorigenesis,
immune unresponsiveness is a feature of established tumors
(18). It is now recognized that tumors can directly or indirectly
impede the development of anti-tumor immune responses
through immunosuppressive cytokines (transforming growth
factor-b and IL-10), T cells with immunosuppressive activities
(regulatory Tcells, 19), inactivation of death receptor signaling
pathways (20) or expression of anti-apoptotic signals (21).
Tumor escape can also result from changes that occur directly
in the tumor, such as loss of antigen expression, loss of MHC
components (22) and development of IFNc insensitivity (23).
This induction of unresponsiveness by tumors can occur either
through anergy or through deletion from resistance mechan-
isms to recognition and killing of tumor cells by activated
immunological effectors. In pediatric ALL, the role of anti-
bodies induced against disease-associated glycotopes re-
mains obscure and accordingly, this study aims to explore
their role in immune surveillance to understand the disease
biology.
The present study has focused on (i) affinity purification of
anti-9-OAcSGs, (ii) analysis of their subclass distribution, (iii)
determination of their total glycosylation and sialylation profile
and (iv) evaluation of the functional activity exerted by anti-9-
OAcSGs.
Methods
Patients and controls
This study included sera from children with confirmed ALL
(n = 50), at presentation of disease, admitted at Vivekananda
Institute of Medical Sciences, Kolkata. Clinical information and
blood samples were sent to Indian Institute of Chemical
Biology. The diagnosis of leukemia was made by standard
cytomorphological and histochemical examination of bone
marrow and blood smears according to French–American–
British classification (24) and by immunophenotyping using
a panel of mAb that included CD 2, 3, 7, 10, 19, 20, 36, 45, 13,
33 and 34 and HLA-DR. The diagnosis was further validated
by FACS analysis using an in-house probe, Achatinin-H (12,
13), specific for 9-OAcSAa2–6GalNAc glycotopes. Patients
with L3 morphology (according to French–American–British
criteria) were excluded. The male/female ratio was 2 : 1, and
median age was 6.2 years with a range of 1.1–17.3 years.
Controls were age-matched normal healthy donors (n = 20).
Informed consent was taken from parents and patients. The
Institutional Human Ethical Clearance Committee approved
the study.
Cell lines
The REH (human B-ALL) and U937 (human promonocytic)
cell lines were purchased from American Type Culture Col-
lection (Manassas, VA, USA). The CEM-C7, a human T-ALL
cell line, was a kind gift from Reinherd Schwartz-Albiez,
Deutsches Krebsforschungszentrum, Heidelberg, Germany
(13). The cells were cultured in RPMI-1640 medium supple-
mented with 10% (v/v) heat-inactivated FCS, 0.002 M L-
glutamine, antibiotics and antimycotics (medium A).
Chemicals and reagents
All chemicals unless stated otherwise were purchased from
Sigma, St. Louis, MO, USA.
Probes
Preparation of bovine submaxillary mucin and its derivatives.
Bovine submaxillary glands were used for purification of
bovine submaxillary mucin (BSM) (25), and protein content
was measured (26). The percentage of 9-OAcSA was
demonstrated by fluorimetric HPLC (27) and quantified as
22.5% by fluorimetric estimation (28).
BSM was de-sialylated (asialo BSM) and de-O-acetylated
(de-OAc BSM) by incubating with 0.25% H2SO4 (0.045 M) for
1 h at 80C and by alkaline hydrolysis with NaOH (0.01 M) for
1 h at 4C, respectively.
Purification of Achatinin-H. Following activation of Sepharose
4B (AmershamBiosciences, Uppsala, Sweden) (29), activated
beads were coupled separately with BSM and asialo BSM
(5 mg ml1 gel). Achatinin-H was affinity purified from the
hemolymph of A. fulica snails using BSM–Sepharose 4B (8) as
it contains a high proportion of 9-OAcSAs linked with subter-
minal N-acetyl galactosamine (GalNAc) of the underlying
oligosaccharide chain (30). Carbohydrate-binding specificity
of purified Achatinin-H toward 9-OAcSAa2–6GalNAc was
established (8) and used as a probe in FACS analysis and for
affinity purification of 9-OAcSGs.
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Purification and characterization of anti-9-OAcSGs. Pooled
sera (~10 ml) from ALL patients at presentation of the disease,
i.e. before any treatment and normal controls, were used to
purify anti-9–OAcSG fractions with preferential affinity for 9-
OAcSAa2–6GalNAc using the method of Pal et al. (15). Briefly,
serum was subjected to a 33% ammonium sulfate fractionation
and sequentially passed through asialo BSM–Sepharose,
BSM–Sepharose and Protein A–Sepharose column (Amer-
sham Biosciences, Uppsala, Sweden). Different subclasses of
IgG were eluted with sodium citrate (0.1 M) using a pH
gradient that ranged from pH 6.0–1.0 followed by immediate
neutralization with 2.0 M Tris and extensive dialysis against
PBS. Purity was tested by SDSP (10%, 31) and subsequent
western blotting using HRP-conjugated goat anti-human IgG
(Jackson ImmunoReasearch Laboratories, Inc., West Grove,
PA, USA). The specificity of Ig subclasses of all these purified
fractions was confirmed by an ELISA.
Specificity of purified anti-9-OAcSGs toward
9-OAcSAa2–6GalNAc
Hemagglutination activity. The biological activities of the
purified antibody fractions were checked by hemagglutination
(HA) (8). The HA titer was reported as the reciprocal of the
highest antibody dilution giving complete agglutination.
The sugar specificity of purified anti-9-OAcSGs was con-
firmed using different sugars (8), and the concentration of
sugar needed for 100% inhibition of HA was determined using
a fixed concentration (16 HA units) of purified antibody.
Flow cytometric analysis revealed binding of purified anti-
bodies to 9-OAcSGs on PBMC of ALL patients. Purified anti-9-
OAcSGs were conjugated with FITC (32). The binding of
FITC–anti-9-OAcSGs (0.5 lg per 106 cells) to cell lines, B-
(REH) and T-ALL (CEM-C7, MOLT-4) and PBMC from both B-
(n = 22) and T-ALL (n = 6) patients along with PE-conjugated
anti-CD 19 or anti-CD 7 (known as B- and T-cell marker,
respectively, BD, Palo Alto, CA, USA) was examined by
staining with respective probes for 1 h at 4C in the dark (33).
The binding was assessed using a FACSCalibur flow cytom-
eter (BD, Palo Alto, CA, USA) and analyzed by CELLQUEST
software (BD, Palo Alto, CA, USA). To confirm the epitope
specificity of purified Igs, cells were pre-incubated with cold
Achatinin-H or pre-treated with O-acetyl esterase, an enzyme
capable of cleaving the 9-O-acetyl group from Neu5Ac (27),
and binding of FITC–anti-9-OAcSGs was determined. Isotype-
matched antibodies served as controls. For each analysis,
10 000 events were recorded.
Confocal microscopy demonstrated binding of purified anti-9-
OAcSGs to ALL cell surface. To visualize the binding of purified
anti-9-OAcSGs to PBMC from both B- and T-ALL patients and
T- and B-ALL cell lines (CEM-C7, MOLT-4 and REH), cells were
incubatedwith FITC-antibodies andobservedunder aconfocal
microscope. Briefly, cells (13 105 cells per 50 ll) were adhered
on poly-L-lysine-coated glass cover slips for 1 h at 20–25C,
fixed with PFA (1%, 100 ll) for 30 min on ice followed by
incubationwith ammoniumchloride (50mM, 100ll) for 5min on
ice. After washing with PBS, they were incubated with FITC–
anti-9-OAcSGs (0.005 lg) for 20 min on ice in the dark. After
washing and mounting, cells were examined under a confocal
scanning microscope (Leica SP2, Leica, Wetzlar, Germany);
the slides were illuminated with a 488-nm laser, and images
were collected using a band-pass filter (505–550 nm) with the
pinhole set at 100 lm.
Quantification of circulating anti-9-OAcSGs. Microtiter plates
were coated with purified BSM (1.0 lg per 100 ll per well) in
0.02 M phosphate buffer, pH 7.4, overnight at 4C. Sera (1 : 10
dilution) were added to the BSM-coated wells, whose non-
specific binding sites had been previously blocked with PBS
containing 2% BSA, and incubated overnight at 4C. The
plates were washed and incubated with different subclasses
of murine anti-human IgG (diluted 1 : 3000, 100 ll per well,
Dianova, Hamburg, Germany), and specific bindings were
captured using HRP-conjugated anti-murine IgG (diluted
1 : 10 000, 100 ll per well, (Jackson ImmunoReasearch Labora-
tories, Inc., West Grove, PA, USA) and detected at 405 nm in
a Multiskan MS Lab Systems ELISA reader using azino-bis
thio-sulfonic acid (Roche Molecular Biochemicals, Mannheim,
Germany) as the substrate. Standard curves generated using
increasing amounts of affinity-purified anti-9-OAcSGs (0–20
lg per 100 ll per well) were applied for quantitation of anti-9-
OAcSGs present in sera.
Analysis of glycosylation of affinity-purified anti-9-OAcSGs
Detection of total glycosylation and sialylation by digoxigenin
enzyme assay. The degree of glycosylation and sialylation was
evaluated by placing an equal amount (1.0 lg per 5.0 ll) of
IgGALL and IgGN by a digoxigenin (DIG) enzyme assay using
a DIG glycan detection kit (Roche Molecular Biochemicals,
Mannheim, Germany) according to manufacturer’s instruc-
tions. DIG-labeled glycoconjugates, present on nitrocellulose
paper, were detected using alkaline phosphatase-conjugated
anti-DIG antibody and visualized with 4-nitroblue tetrazolium
chloride/5-bromo-4-chloro-3-indolyl phosphate as substrate.
The developed spots were scanned and quantified in arbitrary
units using Image Master Totallab Software, version 1.11
(Amersham Pharmacia Biotech, Sweden). Equal amounts
(5.0 lg per 5.0 ll) of transferrin and creatinase were used as
positive and negative controls, respectively.
Quantitation of total Neu5Ac and 9-OAcSA by fluorimetric
estimation. Quantitation of total Neu5Ac and 9-OAcSA was
performed fluorimetrically (28) by oxidizing purified antibodies
(3.0 lg) and processed using acetyl acetone method with or
without saponification of the O-acetyl groups of Neu5Acs.
The relative fluorescence intensity [kmax(excitation=410nm)/kmax
(emission=510nm)] of each sample was measured against reagent
blanks on a Hitachi F-4010 spectrofluorimeter (Tokyo, Japan).
The Neu5Ac content was determined from standard curves
obtained using pure Neu5Ac. The values obtained for the de-
O-acetylated samples indicated total Neu5Ac content, while
the percentage of (8)9-O-acetylated Neu5Ac was determined
by subtracting the respective unsubstituted Neu5Acs from
that obtained after de-O-acetylation.
Detection of neutral sugars by gas–liquid chromatography.
Neutral sugars present in the anti-9-OAcSGs were detected
by gas–liquid chromatography (GLC) as their alditol acetates
(34). The 9-OAcSA-specific IgGs (100 lg each) were hydro-
lyzed with trifluoroacetic acid (2.0 M) at 120C for 90 min,
followed by reduction with sodium borohydride (10 mg).
Resulting alditols were acetylated with acetic anhydride in
distilled pyridine [1 ml, 1 : 1 (v/v)] at 22–25C for 16 h and
analyzed by GLC using a Hewlett-Packard 6890 plus
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gas chromatograph equipped with a flame ionization detector.
The constituent sugars were identified from the retention time
of authentic sugars. For the detection and quantification of
the peaks, a Hewlett-Packard 3380A chemstation was used.
For resolution, a fused-silica capillary column HP-5 (30 m,
0.32 mm, 0.25 lm) and nitrogen as carrier gas were used with
a temperature program of 150C (5 min), 2C (1 min) and
200C (10 min) at splitless mode.
Detection of terminal sugar by DIG glycan differentiation kit.
The presence of terminal sugars along with their specific
linkages was analyzed by DIG glycan differentiation kit (Roche
Molecular Biochemicals, Mannheim, Germany) using several
plant lectins, namely Galanthus nivalis agglutinin (GNA),
Sambucus nigra agglutinin (SNA), Maackia amurensis agglu-
tinin (MAA), peanut agglutinin (PNA) and Datura stramonium
agglutinin (DSA), as per the manufacturer’s protocol.
Lectin bead-binding assay. The purified 9-OAcSA-specific
IgG1 and IgG2 from ALL patients and normal individuals were
iodinated with 125I-Na using the chloramine T method (35).
Fixed concentrations (0.2 lg) of 125I-IgG1 and/or IgG2 were
incubated separately with Sepharose/agarose-bound lectins
(20 ll) of different linkage and specificity, e.g. Con A, Ricinus
communis agglutinin (RCA), Dolichos biflorus agglutinin
(DBA), Helix pomatia agglutinin (HPA), wheat germ agglutinin
(WGA), Ulex europaeus agglutinin (UEA), Limulus polyphe-
mus agglutinin (LPA), MAA, SNA, and Achatinin-H, overnight
at 4C. The beads were initially incubated with 2% BSA in PBS
or Tris-buffered saline (TBS) to block non-specific binding
sites. Following removal of unbound antibody fractions,
specifically bound antibodies were monitored in a gamma
counter. Unconjugated Sepharose/agarose beads served as
controls. Binding (%) was calculated as follows:
Binding ð%Þ=
boundcount control count
Total counts of 125I-antibody used for aparticular set
3 100:
All experiments were performed twice in triplicate.
Evaluation of generation of intracellular reactive oxygen
species as an index for effector cell activation through FccR.
Intracellular reactive oxygen species (ROS) generation was
monitored using a cell-permeable probe 29,79-dichlorofluor-
escein diacetate (H2DCFDA, Molecular Probes, Eugene, OR,
USA), which is oxidized to a fluorescent compound 29,79-
dichlorofluorescein in the presence of an oxidant.
U937 cells were used to analyze the interaction between
FccR present on its surface and the Fc region of anti-9-
OAcSGs, resulting in the triggering of a respiratory burst that is
considered as an indicator of cell activation. The cells were
cultured in medium A in the presence of IFNc (1000 Uml1) for
2 days to induce differentiation and the capacity to generate
superoxide.
To pinpoint the binding of the Fc region of anti-9-OAcSGs
with FccR present on U937 cells, Fab paratopes of these anti-
bodies (total IgG, IgG1and IgG2) were blocked by incubating
them with BSM (1 mg ml1) and/or purified 9-OAcSGs
(0.03 mg ml1) at 4C for 1 h.
These Fab-blocked anti-9-OAcSGs (0.5 lg) were allowed to
bind with IFNc-sensitized U937 cells (1 3 106 cells) for 1 h at
37C and incubated with H2DCFDA (2 lg ml1) for 30 min at
37C in the dark. Following washing, they were analyzed by
flow cytometry and also visualized under a confocal micro-
scope as described earlier. In confocal microscopy, slides
were analyzed in triplicate and total fluorescence was ex-
pressed as fluorescence intensity units (FIU) at 530 nm. Cells
incubated only with BSM and/or purified 9-OAcSGs in the
absence of antibodies served as controls.
Activation of the classical complement pathway. Purified anti-
human C3a chain mAb, SIM 27-49 (36), was iodinated with
125I-Na (35) and used for measuring C3 deposition on the cell
surface due to activation of the classical complement pathway
triggered by anti-9-OAcSGs. Sera (20%) from normal individ-
uals and/or untreated ALL patients were used as the source of
the complement.
Cells (CEM-C7 and REH, 2 3 106 per 100 ll) were
suspended in TBS and allowed to bind with purified anti-9-
OAcSGs (0.1-1.0 lg) as complement activators at 37C for
30 min. EDTA (10 mM) was always used as the blocker of
alternative pathway of complement activation. Following
washing, the cells were incubated with complement (100 ll)
for 10 min at 37C and washed twice in cold TBS, and the
amount of C3 deposition on the cell surface was quantitated
by incubating further with 125I-anti-C3 mAb (2 3 105 counts
per minute) for 1 h on ice. After two washes, the radioactivity
incorporated in C3–anti-C3 complexes was determined by
a gamma counter. Each set was repeated thrice. Cells
incubated with complements or complement activators alone
or complement activators in the presence of heat-inactivated
complement served as different controls.
Evaluation of cytotoxic potential of anti-9-OAcSGs by 51Cr-
release antibody-dependent cell-mediated cytotoxicity assay.
ALLcell lines (CEM-C7andREH)were suspended inmediumA
with human AB serum (10%) and labeled with Na2
51CrO4
(0.1 mCi per 1 3 106 cells, BARC, Mumbai, India; 37) in the
presence and absence of purified anti-9-OAcSGsALL and anti-
9-OAcSGsN (IgG1 and IgG2, 1.0 lg) for 3 h at 37C and 5%
CO2. Cells were washed with the same medium and used as
target cells. Freshly isolatednormal humanPBMCwereusedas
effector cells. Target (1 3 104 cells per 100 ll per well) and
effector cells were co-incubated in a 96-well U-bottom tissue
culture plate for 16 h at 37C in a 5% CO2 environment at E : T
ratios of 5 : 1, 25 : 1, 50 : 1 and 100 : 1. Theplatewas centrifuged
at 500 3 g for 5 min, and the supernatants were checked for
released 51Cr by a gamma counter. Spontaneous release and
maximum release (100% lyses) of 51Cr from labeled target cells
wereevaluated in theabsenceof effectorcells andon treatment
with 5% (v/v) Triton X-100, respectively. Cytotoxicity was
calculated as: 100 3 [(experimental counts  spontaneous
counts)/(maximum counts  spontaneous counts)]. Specific
cell lyses (%) were calculated by normalizing the background
cytotoxicity in the absence of added antibody. All assays were
done in triplicate wells and three independent experiments
were performed for each set.
Interaction of antibodies with Staphylococcal protein A and
Streptococcal protein G. 125I-Labeled anti-9-OAcSGs (IgG1
and IgG2, 0. 2 lg) purified from ALL and normal sera were
separately incubated with Sepharose–Staphylococcal protein
A (SpA) and Streptococcal protein G (SpG) (20 ll) overnight at
4C and specific counts were analyzed as described earlier.
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Experiments were performed in triplicate, and unconjugated
beads served as controls.
Statistical analysis
Results are reported as mean 6 SD. Statistical analyses were
performed using the Graph-Pad Prism statistics software
(Graph-Pad Software Inc., San Diego, CA, USA). Student’s
unpaired t-tests were used. Reported values are two tailed
and P values<0.05 were considered as statistically significant
at 95% confidence interval.
Results
Anti-9-OAcSGs predominantly belong to IgG2
subclass in ALL
Analysis of sera for subclass distribution of anti-9-OAcSGs
demonstrated a 2.78-fold higher concentration of IgG2ALL as
compared with IgG1ALL (158.16 5.57 versus 56.676 3.63 lg
ml1, respectively, P < 0.0001) and a 3-fold increase in
IgG2ALL was quantified than IgG2N (158.16 5.57 versus 51.26
6 4.80 lg ml1, respectively, P < 0.0001). However, the
patient/normal ratio for IgG1, IgG3 and IgG4 subclasses was
lower, being 1.83 (P < 0.0001), 2.29 (P < 0.0001) and 1.34
(P < 0.01), respectively (Fig. 1). The levels of 9-OAcSA-
specific IgG3ALL and IgG4ALL were very low, being 21.26 6
1.12 lg ml1 and 18.86 6 1.84 lg ml1, respectively.
Purified anti-9-OAcSGs are specific for the glycotope
Neu5,9Ac2a2–6b-D-GalNAc
Purification of anti-9-OAcSGs revealed a 3-fold higher in-
duction of IgGALL as comparedwith IgGN (96.296 4.22 versus
31.466 3.07 lg ml1, respectively). The specificity of purified
anti-9-OAcSGs was analyzed by a HA assay. Rabbit eryth-
rocytes, containing a high percentage of 9-OAcSA on their cell
surface, showed a maximum HA titer, whereas human
erythrocytes of different blood groups, which contain only
Neu5Ac and importantly no 9-OAcSA (38), did not agglutinate
(Table 1). Although the percentage of 9-OAcSA in the other
species had a narrow range of 20–25%, a far wider variation in
the HA titer was observed, possibly reflecting the variability in
accessibility of the 9-OAcSA residues. The specificity of these
antibody fractions toward Neu5,9Ac2a2–6b-D-GalNAc was
further substantiated by HA inhibition assays using free 9-
OAcSA as well as several sialoglycoproteins (Table 2). All four
subclasses of antibodies preferentially bound to BSM having
terminal 9-OAcSA and subterminal GalNAc in an a2–6 linkage.
The absence of inhibition with de-OAc BSM, asialo BSM, SSM,
HCG and fetuin reconfirmed its specificity. However, the
antigens present in BSM could be either in a mono-, di-, or tri-
O-acetylated form, which the purified antibody possibly
cannot distinguish.
Purified anti-9-OAcSGs bind to ALL blasts but not with
normal PBMCs
Flow cytometric analysis revealed that FITC–anti-9-OAcSG-
sALL bind strongly with PBMCALL (87–99%, n = 28) irrespective
of their lineage, whereas PBMCN showed negligible binding
(8–14%, n = 14). This binding was confined to O-AcSGs as
the antibody binding was reduced in PBMCALL by 87.5%
when cells were pre-incubated with 5.0 lg unconjugated
Achatinin-H prior to incubation with FITC–anti-9-OAcSGsALL
(96 versus 12%, Fig. 2A). Similarly, their pre-treatment with O-
acetyl esterase caused 85–92% reduction. ALL cell lines (both
B and T) also showed similar binding profiles.
These purified antibodies consistently demonstrated sur-
face binding with PBMCALL and cell lines, irrespective of the
lineages, as evidenced by confocal microscopy (Fig. 2B);
binding with normal PBMCs was negligible (data not shown).
Fig. 1. Subclass distribution of 9-OAcSA-specific IgGs in ALL patients
andnormal individuals. Levelsof anti-9-OAcSGs: IgG1 (openbar), IgG2
(filled bar), IgG3 (dotted bar) and IgG4 (shaded bar) were quantified in
sera of ALL patients at disease presentation along with normal donors
(N)byanELISAusingBSMascoatingantigenasdescribed inMethods.
Data are expressed as mean 6 SD of absolute quantitation (lg ml1).
Significant differences between mean values: *P < 0.0001; **P <
0.0001; ***P < 0.0001; #P < 0.0001 and ##P < 0.01.
Table 1. HA of erythrocytes by purified anti-9-OAcSGs
Erythrocytesa Position of major
O-acetylated group
OAcSA
content (%)b
HAc
Human A — 0 0
Human B — 0 0
Human O — 0 0
Guinea pig C-9 22 8
Rabbit C-9 20 512
Rat C-9 25 4
Hamster C-9 22 8
aErythrocytes (2%, v/v) were incubated with purified antibody
fractions for their agglutination (8). bFluorimetric estimation of
percentage of 9-O-acetylated Neu5Acs according to the method of
Shukla and Schauer (28). cThe HA titer was reported as the reciprocal
of the highest antibody dilution giving complete agglutination. Four
subclasses of anti-9-OAcSGs showed comparable results.
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Anti-9-OAcSGs in ALL patients (IgGALL) differ in the nature
and content of glycosylation from those of normal
individuals (IgGN)
The degree of glycosylation (Fig. 3A and B) and specifically
sialylation (Fig. 3C) of 9-OAcSA-specific purified IgGs was
demonstrated using the DIG glycan detection kit. A 2.1-fold
increase in overall glycosylation was observed in IgGALL as
compared with IgGN, the mean6 SD of densitometric score in
arbitrary units being 80 651 6 8210 versus 38 232 6 5100,
respectively, P < 0.0006 (Fig. 3B).
However, the Neu5Ac content was 3.6-fold higher in ALL
patients than normal controls (densitometric scores being
15 207 6 2370 versus 4224 6 642, respectively, P < 0.008,
Fig. 3C). The presence of high amount of Neu5Acs in anti-9-
OAcSGsALL was corroborated by fluorimetric estimation of
their (IgG, IgG1 and IgG2) Neu5Ac content as compared with
their normal counterparts, the concentrations being 3.3- (P <
0.0002), 2.9- (P < 0.0001) and 3.2-fold (P < 0.005) higher in
ALL antibodies, respectively. Interestingly, Neu5Ac content of
IgG2ALL was found to be higher than IgG1ALL, mean 6 SD
being 40.06 2.0 versus 25.36 1.6 ng of Neu5Ac per 1.0 lg of
Igs (P < 0.0006, Fig. 3D). However, no measurable difference
was observed in the (8)9-O-acetylated Neu5Ac content of
antibody fractions in ALL patients versus normal controls.
To trace the content of individual neutral sugars present in
anti-9-OAcSGs purified from ALL patients and normal individ-
uals, GLC analysis was performed. The gas–liquid chromato-
gram peaks revealed a significantly higher amount of N-acetyl
glucosamine (GlcNAc) in IgGALL (Fig. 4A) and galactose (Gal)
in IgGN (Fig. 4B). As compared with normal controls, IgGALL
Fig. 2. (A) Purified anti-9-OAcSGs bind to lymphoblasts of ALL patients. A representative profile of the flow cytometric analysis revealing specific
binding of affinity-purified FITC–anti-9-OAcSGs to PBMCALL as described in Methods. Peaks 1 and 2 represent high expression of 9-OAcSGs on
PBMCALL using FITC–anti-9-OAcSGs (IgG1ALL) and FITC–Achatinin-H, respectively. Specificity of antibody binding was demonstrated by binding
of anti-9-OAcSGs to PBMCALL following pre-incubation with unconjugated Achatinin-H (peak 3). Peak 4 represents binding with control antibody.
(B) Visualization of binding of anti-9-OAcSGs to the ALL cell surface by confocal microscopy. FITC–anti-9-OAcSGs were targeted toward PBMCALL
(1 3 105 cells per 50 ll) of both the lineages, ALL cell lines as well as PBMCN, for 20 min on ice in the dark and visualized under a confocal
scanning microscope (Leica SP2, Leica, Wetzlar, Germany) as described in Methods. A representative slide consisting of phase contrast,
fluorescence and overlaid images of ALL PBMC is documented.
Table 2. Sugar specificity of purified anti-9-OAcSGs by HA
inhibition assays
Sugars Terminal linkages Relative inhibitory
potency (%)a
Monosaccharide Neu5,9Ac2 0.17
BSM Neu5,9Ac2a2–6b-D-GalNAc 100.00
de-OAc BSM Neu5Aca2–6b-D-GalNAc Nil
Asialo BSM GalNAc Nil
SSM Neu5Aca2–6b-D-GalNAc Nil
HCG Neu5Aca2–3b-D-Gal Nil
Fetuin Neu5Aca2–6b-D-Gal Nil
SSM, sheep submaxillary mucin; HCG, human chorionic gonadotro-
phin; and Nil, no inhibition. Four subclasses of anti-9-OAcSGs
showed comparable result.
aTheminimal concentration of sugars or glycoproteins required for total
inhibition of HA of rabbit erythrocytes (2%, v/v) induced by 16 HA units
of purified anti-9-OAcSGs is the inhibitory concentration/potency (8).
Considering the inhibitory potency of BSMas 100, the relative inhibitory
potency of different sialoglycoproteins/sugars are calculated.
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had a higher amount of GlcNAc (relative percent area of the
peak being 6.86 versus 29.88), GalNAc (4.81 versus 9.04%)
and mannose (10.24 versus 13.28%), whereas the amount of
Gal was marginally higher in IgGN than IgGALL (32.002 versus
21.64%, respectively, Fig. 4A and B).
Although GLC analysis showed differences in the total
content of neutral sugars, it would be interesting to explore
the linkage-specific arrangement of terminal sugars of IgG-
glycans. With this view, we have exploited the binding
specificity of various well-established lectins toward known
terminal sugar moiety in the analysis of glycans present in anti-
9-OAcSGs (IgG1 and IgG2) purified from ALL patients (n = 4)
and normal control (n = 4) using DIG glycan differentiation kit
(Fig. 5). The binding of GNA [specific for terminal Mana(1–3),
(1–6) and (1–2)Man] to IgG1ALL and IgG2ALL was the weakest,
being almost 38- (P < 0.0001) and 19-fold (P < 0.0001) lower
than that of IgG1N and IgG2N, indicating a lower content of
terminal mannose residues in anti-9-OAcSGsALL, possibly
resulting from masking of terminal mannose residues by
Neu5Acs. Interestingly, binding with SNA [specific for Neu5-
Aca(2–6)Gal/GalNAc] revealed a 5.9-fold higher binding to
IgG1ALL than that of MAA (densitometric score being 73 2576
1749 versus 12 221 6 937, respectively, P < 0.0001),
reflecting the enhanced presence of Neu5Acs with a sub-
terminal a2–6 linkage than a2–3 linkage. Similarly, IgG2ALL
showed a 4.8-fold higher binding (P < 0.001) with SNA than
MAA. On the contrary, both IgG1N and IgG2N demonstrated
no difference in binding with SNA and MAA. An overall ~2-fold
higher SNA binding was observed in both IgG1ALL and
IgG2ALL (P < 0.0001) than in their normal counterparts.
The binding of DSA [specific for Galb(1–4)GlcNAc] and
PNA [specific for Galb(1–3) GalNAc] with anti-9-OAcSGs was
in general very low in both ALL patients and normal controls
(Fig. 5).
Binding of 125I-anti-9-OAcSGs with several Neu5Ac-binding
lectins, e.g. WGA (GlcNAc/Neu5Ac), LPA (Neu5Ac), SNA and
MAA, also indicated a higher degree of sialylation in IgGALL
(Table 3). Other lectins, namely RCA, DBA, HPA, UEA and
Achatinin-H, showed no marked difference in their binding. In
contrast, a 5.9-fold higher ConA (a-Man, a-Glc) binding with
IgGN indicated an abundance of terminal mannose residues in
normal antibodies.
Taken together, the observation suggests wide variations
in glycosylation pattern specifically induced in 9-OAcSA-
specific IgG1ALL and IgG2ALL as compared with their normal
counterparts.
Fig. 3. Differential glycosylation and sialylation of anti-9-OAcSGs. (A) A representative profile of glycosylation pattern in anti-9-OAcSGs (IgG) of
ALL patients (n ¼ 4, ALL) and normal donors (n ¼ 4, N). Equal amounts (1.0 lg) of affinity-purified Igs were blotted on to nitrocellulose membrane
and processed for the detection of neutral sugars using a DIG glycan detection kit. (B) The intensities of the developed spots were quantified using
Image Master Totallab Software, version 1.11 (Amersham Pharmacia Biotech). Results were reported as mean 6 SD of densitometric score in
arbritary units from two independent experiments. Transferrin (T) and creatinase (C) were used as positive and negative controls, respectively. #1,
significant differences between mean values, P < 0.0006. (C) The degree of sialylation of all these samples were detected by DIG enzyme assay
using DIG glycan detection kit as described in Methods. Spot intensities were stated as mean 6 SD of densitometric score in arbitrary units. #2,
significant differences between mean values, P < 0.008. (D) The Neu5Ac contents in purified anti-9-OAcSGs were detected by fluorimetric
estimation. Purified antibodies from ALL patients (open bar) and normal individuals (filled bar) were processed as described in Methods (27).
Significant differences between mean values, #3, P < 0.0002; #4, P < 0.0001; #5, P < 0.005 and *, P < 0.0006.
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9-OAcSA-specific IgGALL are less potent activators of
U937 cells through Fcc–FccR interaction as compared
with IgGN
Following the blocking of Fab regions of purified anti-9-
OAcSGs by BSM or purified 9-OAcSGs, the antibodies were
incubated with IFNc-sensitized U937 cells to compare their
ability to activate these cells via interaction with FccR. The
generation of intracellular ROS was considered as an index for
cell activation that was monitored using H2DCFDA, which
primarily detects H2O2 and hydroxyl radicals. Flow cytometric
analyses revealed that anti-9-OAcSGsALL caused a signifi-
cantly lower level of FccR activation as reflected from 45, 50
Fig. 4. Analysis of carbohydrate composition of anti-9-OAcSGs by GLC. The 9-OAcSA-specific IgGALL and IgGN (100 lg each) were analyzed by
GLC as stated in Methods. Response (in pA) was plotted against retention time (min). The representative profile of individual peaks revealed the
differential expression of GlcNAc and GalNAc (A) and mannose and galactose (B).
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and 36%ROS-generating cells induced by total IgG, IgG1 and
IgG2, respectively. In contrast, anti-9-OAcSGsN (total IgG and
IgG1) demonstrated significantly higher ROS-generating cells
(90 and 93%, respectively). Anti-9-OAcSGsN of IgG2 sub-
class, on the other hand, showed only 41% ROS-generating
activity (Fig. 6A).
This observation was further validated using laser-scanning
confocal microscopy wherein a decreased H2DCFDA fluores-
cence was observed in cells that were targeted either with IgG
or IgG1 of anti-9-OAcSGsALL, the FIU at 530 nm being 25.2 6
3.7 and 30.8 6 3.63, respectively (Fig. 6B and C). In contrast,
cells probed with anti-9-OAcSGsN (IgG and IgG1) showed a
4.0- (P < 0.0007) and 4.5-fold (P < 0.0003) rise in ROS gen-
eration, the FIU at 530 nm being 100.0 6 13.91 and 140.2 6
16.30, respectively, in comparison to IgG and IgG1 of anti-9-
OAcSGsALL. The IgG2 subclass anti-9-OAcSGs from both
sources could not induce ROS generation and control sets
showed negligible fluorescence.
Anti-9-OAcSGs from ALL patients (IgGALL) are poor
activators of the classical complement pathway
The potential of anti-9-OAcSGsALL (IgG1 and IgG2; 0.1, 0.5
and 1.0 lg) to activate the classical complement pathway was
compared with anti-9-OAcSGsN using cell lines CEM-C7
(Fig. 7A) and REH (Fig. 7B) in the presence of 20% ALL sera
and/or normal sera as the source of complement. Maximum
differences in complement activation were observed with 1.0 lg
concentration of anti-9-OAcSGs (complement activator).
IgG1N was found to be the only potent activator of classical
complement pathway as reflected by a gradual increase in C3
deposition, maximum being 91–94% (Fig. 7A and B; Table 4).
However, in both cell lines, 9-OAcSA-specific IgG1ALL,
IgG2ALL and IgG2N (0.1–1.0 lg) consistently showed low
complement activation, C3 deposition being 21–29, 19–26
and 24–27%, respectively, using 1.0 lg of complement
activators.
A similar amount of C3 deposition was observed irrespect-
ive of the source of complement used (ALL or normal human
sera), suggesting undisturbed complement components in
disease state.
To confirm that this C3 deposition was due to activation of
the complement pathway, cells were incubated with anti-
bodies or sera alone, or antibodies along with heat-inactivated
sera. All controls consistently demonstrated an inability to
trigger C3 deposition on both cell types, the range of C3
deposition being 2–16% (Table 4, Fig. 7A and B).
Fig. 5. Differential glycosylation pattern in anti-9-OAcSGs as detected
by DIG enzyme assay. Purified 9-OAcSA-specific Igs (IgG1, n ¼ 4,
and IgG2, n ¼ 4) from ALL patients (open bar) and normal individuals
(filled bar) were analyzed for detection and linkage specificity of
carbohydrate chains using different lectins, namely GNA, SNA, MAA,
PNA and DSA, by DIG glycan differentiation kit as described in
Methods. Results were reported as mean6 SD of densitometric score
in arbitrary units from two independent experiments. Carboxypepti-
dase Y (GNA+), transferrin (SNA+), fetuin (SNA, MAA and DSA+) and
asialofetuin (PNA and DSA+) were used as positive controls.
*Significant differences between mean values, P < 0.0001.
Table 3. Binding of 125I-anti-9-OAcSGs with lectin beads
Lectin Sugar and linkage specificity Binding (%)
IgG1 IgG2
Patient Normal Patient Normal
RCA b-D-Gal 33.14 20.97 36.44 25.39
DBA a-GalNAc 14.92 11.17 12.68 15.42
HPA a- or b-D-GalNAc 17.58 12.33 19.53 13.41
UEA a-L-Fuc 18.54 21.82 21.14 25.60
Con A a-Man, a-Glc 7.79 46.25 12.14 50.76
WGA GlcNAc/Neu5Ac 21.50 7.09 17.71 10.14
LPA Neu5Ac 31.43 16.51 34.04 15.72
SNA Neu5Aca2–6Gal/GalNAc 22.89 9.73 24.74 13.27
MAA Neu5Aca2–3Gal 17.89 38.37 13.34 39.41
Achatinin-H Neu5,9Ac2a2–6b-D-GalNAc 17.05 14.72 15.33 20.13
Affinity-purified 125I-anti-9-OAcSGs (IgG1 and IgG2, 0.2 lg) from patients and normal controls were incubated with Sepharose/agarose-bound
lectins (20 ll) of different linkage and specificity as described in Methods. Unconjugated Sepharose/agarose beads served as controls. Binding
(%) was determined from the specific binding of iodinated antibodies to lectin beads with respect to the total counts of the radio-labeled
antibodies used for that particular set. All experiments were performed twice in triplicate, and a representative profile was reported here.
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Anti-9-OAcSGsALL (IgG1 and IgG2) are weak mediators for
cell-mediated cytotoxicity
To confirm differential functional potential of anti-9-OAcSGs, 9-
OAcSA-specific IgG1 and IgG2 from ALL patients and normal
individuals were used as mediators for cytotoxic activity of
effector cells toward both T- and B-ALL cell lines. Optimum
cytotoxicity was observed at 50 : 1 effector/target cell ratio. The
9-OAcSA-specific IgG1ALL and IgG2ALL were found to be poor
mediators of antibody-dependent cell-mediated cytotoxicity
(ADCC) as evidenced from 6–10% and 4–5% specific cell
lyses in REH and CEM-C7 cell lines, respectively. Anti-9-
OAcSGsN (IgG2) also showed a similar pattern of cytolysis (2–
5%). In contrast to anti-9-OAcSGsN (IgG2), anti-9-OAcSGsN
(IgG1) was capable of mediating a high degree of cytotoxicity
in both the cell lines, mean specific cell lyses being 62%
(P < 0.0006) and 42% (P < 0.0007) for REH and CEM-C7,
respectively. Again, anti-9-OAcSGsN (IgG1) was found to be
6- (P < 0.0009) and 7-fold (P < 0.001) more effective in lysing
REH and CEM-C7, respectively, than anti-9-OAcSGsALL
(IgG1).
Both IgGALL and IgGN showed similar interactions with
SpA and SpG
The interaction of 125I-anti-9-OAcSGs (IgG1 and IgG2)
purified from ALL patients and normal individuals with SpA
and SpG was similar. The specific binding (counts per minute,
mean 6 SD) of IgG1ALL and IgG1N to SpA was 14 609 6 673
versus 13 711 6 541, and that to SpG was 17 021 6 796
versus 17 9356 982, respectively. A similar pattern of binding
was observed between IgG2ALL and IgG2N to SpA (11 323 6
716 versus 13 010 6 460) and SpG (14 709 6 683 versus
12 907 6 557).
Discussion
The conundrum of cancer immune surveillance indicates that
the immune system not only can protect the host against tumor
development but conversely also has the capacity to promote
tumor growth, especially those with lower immunogenicity
(18). Induction of disease-specific 9-OAcSGs on PBMC of
childhood ALL (12, 33) was found to be highly immunogenic
(15) and the diagnostic potential of anti-9-OAcSGs has been
extensively demonstrated (16). However, assessment of their
biological role in ALL is a relatively new domain in leukemia
sialobiology. With this aim we were interested to explore the
probable role of the disease-specific antibodies to provide an
insight into the biology of this disease. The presence of a small
fraction of antibodies against 9-OAcSGs mainly of IgG2 in
normal human serum has long been identified (39), but
progress in assigning it a biological role is still in its infancy.
The major findings of this investigation include the demon-
stration of (i) a shift in subclass distribution of anti-9-
OAcSGsALL toward IgG2 (Fig. 1), (ii) an alteration in total
content and pattern of glycosylation including variation in the
linkage-specific terminal Neu5Ac residues in anti-9-OAcSGs
in ALL as compared with their normal counterparts (Figs 3–5)
and (iii) defective triggering of a few Fc-glycosylation-sensitive
effector functions in anti-9-OAcSGsALL (Figs 6–8), while their
antigen-binding property remained unaffected (Fig. 2).
A 3-fold higher amount of anti-9-OAcSGs in ALL patients’
sera was present as compared with normal individuals. A
defined specificity of different subclasses of purified anti-9-
OAcSGs toward the glycotope Neu5,9Ac2a2–6b-D-GalNAc
was documented by HA and HA inhibition assays (Tables 1
and 2), flow cytometry (Fig. 2A) and confocal microscopy
(Fig. 2B).
Fig. 6. Differential activation of FccR by anti-9-OAcSGs as determined
by intracellular respiratory burst. Fab-blocked anti-9-OAcSGsALL and
anti-9-OAcSGsN (IgG, IgG1 and IgG2) were compared for their FccR-
mediated U937 cell-activation potential as described in Methods.
H2DCFDA was used as the probe to monitor the generation of ROS by
flow cytometry (A) and confocal microscopy (B). FACS analyses were
represented by FL1-H histogram plot. Cells incubated with BSM and/
or purified 9-OAcSGs served as controls (C, filled area). Anti-9-
OAcSGsALL- and anti-9-OAcSGsN-treated cells were shown as ALL
and N, respectively (A). Confocal micrographs were reported as
panels for fluorescence and phase contrast (B). (C) Bar graphs
showing total ROS generation within U937 cells upon exposure to IgG,
IgG1and IgG2 of anti-9-OAcSGsALL (ALL) and anti-9-OAcSGsN (N).
Data are represented in FIU at 530 nm. Significant differences
between mean values: *P < 0.0007, **P < 0.0003.
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Both IgG1 and IgG2 of purified anti-9-OAcSGsALL showed
strong binding (87–99%) with PBMCALL, suggesting their fully
functional antigen-binding capacity. The total absence of
binding of anti-9-OAcSGsALL with PBMC from various cross-
reactive disorders like chronic myelogenous leukemia, acute
myelogenous leukemia (AML), chronic lymphocytic leukemia
(CLL), non-Hodgkin’s lymphoma (NHL), adult ALL, aplastic
anemia and thalassemia reiterated its disease specificity.
Additionally, weak binding (8–14%) of anti-9-OAcSGsALL
(IgG1 and IgG2) with PBMCN reconfirmed a basal level of
expression of 9-OAcSGs on PBMCN as indicated by our earlier
observation (12).
Although differential distribution in levels of IgG subclasses
is reported in several diseases, disease-specific distinct
Fig. 6. Continued.
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pattern is restricted to only a few. Accordingly, we attempted to
analyze the status of 9-OAcSA-specific IgG subclasses in
ALL. A predominance of IgG2 among all four subclasses in
these children was demonstrated as evidenced by a 2.78-fold
higher amount of IgG2ALL as compared with IgG1ALL (158.16
5.57 versus 56.67 6 3.63 lg ml1, respectively, Fig. 1).
Interestingly, the level of 9-OAcSA-specific IgG2 was much
higher (3-fold) in ALL patients than normal controls (158.1 6
5.57 versus 51.266 4.80 lg ml1, respectively), indicating the
high immunogenicity of 9-OAcSGs in disease state and their
efficient modulation for disease-specific alteration in isotype
subclass switching toward IgG2. Patients with gynecological
malignancies (40) and squamous cell carcinomas of head and
neck (41) exhibited a characteristic decrease in IgG1 and an
increase in IgG2 levels, relative to total IgG.
IgG, a multifunctional glycoprotein, comprises two distinct
functional domains, expressing an antigen-specific binding
site (IgG-Fab), while the IgG-Fc is responsible for triggering
effector mechanisms through its interaction with specific
ligands, e.g. cellular receptors (FccR) and the C1 component
of complement (42). The IgG-Fc is a homodimer comprising
inter-chain disulfide-bonded hinge regions, glycosylated CH2
domains and non-covalently paired CH3 domains (42).
Glycosylation of IgG-Fc has been shown to be essential for
efficient activation of FccR and C1 component of complement
(42). The oligosaccharide profiles of the IgG are significantly
influenced by disease stress, nutrient depletion or acid pH,
resulting in hypogalactosylation or the addition of high
mannose forms or failure of glycosylation (42). IgGs isolated
from sera of patients with multiple myeloma, CLL and AML
showed altered levels of fucose, Gal and bisecting GlcNAc as
compared with normal (43–45). Based on these observations,
we endeavored to analyze the glycosylation profile of different
subclasses of monospecific polyclonal anti-9-OAcSGs spe-
cifically induced in sera of patients with childhood ALL and
compared them with normal individuals.
Fig. 7. Activation of the classical complement pathway by anti-9-OAcSGsALL and anti-9-OAcSGsN (IgG1 and IgG2). CEM-C7 (T-ALL, A) and REH
(B-ALL, B) cells (2 3 106) were incubated separately with anti-9-OAcSGsALL and anti-9-OAcSGsN (0.1, 0.5 and 1.0 lg) at 37C for 30 min (filled
circle, ALL IgG1; open circle, normal IgG1; filled square, ALL IgG2; and open square, normal IgG2) using either 20% ALL sera (continuous lines)
or normal sera (dotted lines) as the source of complement. Activation of classical complement pathway was monitored by C3 deposition on cell
surface using 125I-anti-C3 mAb as described in Methods. C3 deposition was represented as percentage of specific binding of antibody (mean6
SD of triplicate values). Cells incubated with complement alone, antibody alone and antibody along with heat-inactivated complements served as
controls.
Table 4. Impairment in complement activation by anti-9-
OAcSGsALL as demonstrated by C3 deposition
Complement
activators
Complement
sources
Cell lines
T-ALL B-ALL
Anti-9-OAcSGs (1.0 lg) Serum (20%) CEM-C7 REH
IgG1ALL AS 29 21
NS 21 24
IgG1N AS 92 91
NS 94 93
IgG2ALL AS 19 19
NS 20 26
IgG2N AS 24 27
NS 26 25
— AS 4 3
— NS 2 8
IgG1ALL — 7 5
IgG1N — 3 6
IgG2ALL — 8 3
IgG2N — 4 5
IgG1ALL HI-AS 9 2
HI-NS 11 8
IgG1N HI-AS 6 16
HI-NS 13 4
IgG2ALL HI-AS 8 9
HI-NS 5 7
IgG2N HI-AS 14 11
HI-NS 8 5
Comparative potential of anti-9-OAcSGs (IgG1 and IgG2; 1.0 lg),
purified from ALL patients and normal individuals, to activate the
classical complement pathway was assessed using CEM-C7 (T-ALL)
and REH (B-ALL) cells and 20% ALL sera (AS) and/or normal sera
(NS) as the source of complement as described in Methods. The C3
deposition on the cell surface was considered as the index for
complement activation and was presented as specific binding (%)
of 125I-anti-C3 mAb (mean of triplicate values). Cells incubated with
complement alone, antibody alone and antibody along with heat-
inactivated complements (HI-AS and HI-NS) served as controls. ‘—’
indicates absence of particular component.
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A wide variation in the degree of total glycosylation and
specifically sialylation was observed in anti-9-OAcSGs as
reflected by 2.1- and 3.6-fold higher level of glycosylation and
sialylation in ALL patients as compared with their normal
counterparts (Fig. 3A–C). This was confirmed by fluorimetric
analysis that showed a similar increase in sialylation of IgGALL
as compared with IgGN (Fig. 3D). A significantly high
proportion of SNA binding with IgGALL (IgG1 and IgG2) as
compared with MAA binding implies an enhanced induction of
terminal Neu5Aca2–6Gal/GalNAc with concomitant reduction
in terminal Neu5Aca2–3Gal (Fig. 5). IgGN showed a similar
type of specificity toward SNA and MAA binding; however, the
degree of binding was much lower than that of IgGALL. The
conspicuously lower amount of terminal mannose both in
IgG1ALL and IgG2ALL, as reflected from GNA and Con A
binding, could be attributed to their being masked by a2–6-
linked Neu5Acs, possibly a characteristic feature of this
disease (Fig. 5, Table 3).
Taken together, it has been convincingly demonstrated that
9-OAcSA-specific IgGALL differ both in their content and
nature of glycosylation as compared with IgGN. Although
a distinct disease-specific pattern of terminal and subterminal
sugar moieties has emerged, a chemical analysis of total
glycan structure of Igs from individual patients would be of
utmost importance.
Glycoproteins are key components of the immune system
effectors even though the attached sugar moieties often
deviate greatly from their appropriate homogeneous geo-
metrical array, thus affecting the activation of proper immune
response. The ubiquity and diversity of protein glycosylation is
not a paradox, but consistent with functional rules (46). Human
IgG ispredominantly glycosylatedwithN-linkedcarbohydrates
and conserved glycosylation of the Fc region occurs at
asparagine 297 (Asn297), from which two opposing bi-
antennary oligosaccharide chains protrude and interact.
Crystallographic studies have shown that the twoCH2 domains
do not interact by protein–protein contacts, but instead through
oligosaccharides attached at the conserved site of Asn297 on
each heavy chain. Protein–oligosaccharide and oligosaccha-
ride–oligosaccharide interactions play amajor role in maintain-
ing the relative geometry of the CH2 domains, consistent with
the biological role of IgG (47).
As mediators of the humoral immune response, antibodies
bind to specific antigens through Fab and then trigger
biological responses by interacting through their Fc region
with both cellular and soluble effector systems. It has been
reported that heavy chain-linked conserved glycans of IgGs at
Asn297 significantly contribute to their effector properties by
influencing the complement activation via the classical
pathway, which begins with the binding of C1q component
of the complement to the CH2 domain of the IgG molecule,
binding of IgGs to FccR and subsequent cellular function,
induction of ADCC and also rapid elimination of the antigen–
antibody complexes from the circulation (42, 48, 49).
Analysis of effector function of anti-9-OAcSGs revealed that
FccR-activating capacity was much lower in IgG1ALL as
evidenced from a decrease in the percentage of ROS-
generating cells, when U937 cells, known to contain a high
amount of FccRI on their surface, were targeted with Fab-
blocked antibodies, suggesting their functional impairment
(Fig. 6A). Whereas IgG1N was fully capable of activating 91%
U937 cells for ROS generation. This was corroborated with
confocal microscopy (Fig. 6B and C). Similarly, the capacity of
FccR triggering was decreased both in IgG2ALL and IgG2N,
ROS positivity being 35 and 39%, respectively (Fig. 6A). The
efficiency of normal human IgG2 in binding to FccR is reported
to be the lowest among all the subclasses of IgG, the
efficiency decreases in the following order IgG1 = IgG3 >
IgG4\ IgG2 (49). The predominance of 2.8-fold increased
production of 9-OAcSA-specific IgG2 (Fig. 1) along with low
amounts of non-functional IgG1 in ALL patients suggests the
inappropriate immune surveillance.
The impaired functioning of 9-OAcSA-specific IgG1ALL and
IgG2ALL has further been demonstrated by their diminished
complement activation as reflected from less C3 deposition
(Fig. 7, Table 4). Notably, IgG1N was found to be the only po-
tential activator of classical complement pathway. Consider-
ing the fact that antibody binding to C1q does not guarantee
the activation of C1 (50), we checked the C3 deposition,
a downstream component, to get the assurance of activated
complement cascade. Nature of the terminal sugars on Fc-
glycans is known to influence the activation of C1 (42).
ADCC experiments using IgG1 and IgG2 subclasses of
anti-9-OAcSGsALL and anti-9-OAcSGsN as mediators clearly
demonstrate the inability of anti-9-OAcSGsALL to elicit any
specific cytolysis (Fig. 8), thereby further strengthening the ob-
served impairment of their proper biological functioning as evi-
denced from their low FccR-activating capacity (Fig. 6A–C) and
diminished complement activation potential (Fig. 7, Table 4).
SpA and SpG are known to bind to IgG-Fc at the interface
between the CH2 and CH3 domains of the Fc through
Fig. 8. Efficacy of anti-9-OAcSGs as potent mediator of cell-mediated
cytotoxicity by 51Cr-release assay. ALL cell lines (REH and CEM-C7)
were labeled with Na512 CrO4 in the presence and absence of purified
antibodies (0.01 lg per 1 3 104 cells) and used as target cells. Four
different types of antibodies [anti-9-OAcSGsN (IgG1, filled bar; IgG2,
open bar) and anti-9-OAcSGsALL (IgG1, ; IgG2, )] were used as
mediators of cytotoxicity. Freshly isolated normal human PBMC were
used as effector cells. Target (1 3 104 cells per 100 ll per well) and
effector cells were co-incubated and checked for released 51Cr as
described in Methods. Specific cell lyses (%) were calculated by
normalizing the background cytotoxicity in the absence of added
antibody. Optimum cytotoxicity (50 : 1 effector/target cell ratio) was
demonstrated in bar graphs (mean 6 SD of triplicate values).
Significant differences between mean values: *P < 0.0006; **P <
0.0009; #P < 0.0007; ##P < 0.001.
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hydrophobic interactions (51). X-ray crystallographic and
NMRstudies clearly illustrated the negligible role of differences
in IgG-Fc glycosylation in their SpA and SpG binding (42).
Interestingly, our observation also demonstrates the similar
binding profile of anti-9-OAcSGs (IgG1 and IgG2) with Protein
A and G, irrespective of the source of antibodies, i.e. patient or
normal sera.
In spite of several attempts by using glycosylation inhibitor,
site-directed mutagenesis and enzymatic addition of particu-
lar sugar to analyze the direct influence of distinct glycosyla-
tion profile on functional activity of IgG, the underlying
mechanism still remains unclear (49). However, dramatic
differences in functional activity of IgGs were observed
between fully glycosylated and molecular variants with
selectively modified glycosylation or aglycosylated forms
(42). If receptor/ligand interactions are modulated by glyco-
sylation differences, the protective effector mechanisms
activated by an oligoclonal-specific antibody population could
be dependent on the predominant glycoforms present (49).
This suggests an interesting possibility since IgG antibody
responses can be subclass and clonally restricted and the
glycosylation profiles of these antibodies may also be re-
stricted as observed for IgG myeloma proteins (49). Surpriz-
ingly, passive immunization with anti-tumor antibodies did not
protect against tumor growth, in many cases they actually
enhanced the growth of the tumor (52).
In summary, this report established significant differences in
glycosylation (mainly sialylation) and several functional prop-
erties between the 9-OAcSA-specific Igs from ALL patients
and normal individuals and suggested anti-9-OAcSGs-mediated
impairment of proper immune clearance in ALL. In the future,
we hope to address the direct correlation between observed
structural heterogeneity in glycosylation and the impaired
functions of anti-9-OAcSGs in ALL by analyzing the confor-
mational changes of Fc-carbohydrates, changes in topog-
raphy of ligand-binding sites and subsequently their functional
properties using different truncated glycoforms and also
considering an individualistic approach. Studies with soluble
recombinant FccRI or FccR knockouts would also provide
confirmatory evidence.
Considering the phenomena of subclass switching from
IgG1 to IgG2, their heterogeneous glycosylation, preferential
sialylation along with the impairment of function (activation of
FccR and complement) in ALL patients, the generation of
customized antibody constructs bearing functional Fc domain
of anti-9-OAcSGs-IgG1, having a homogenous glycoform and
a predetermined profile of functional potential, might lead to
their effective functioning. Such customized antibodies might
be used in conjugation with cytokine therapy to activate in vivo
anti-cancer pathways for proper immune surveillance in
pediatric ALL.
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Abbreviations
ADCC antibody-dependent cell-mediated cytotoxicity
ALL acute lymphoblastic leukemia
AML acute myelogenous leukemia
Asialo BSM de-sialylated BSM
BSM bovine submaxillary mucin
CLL chronic lymphocytic leukemia
de-OAc BSM de-O-acetylated BSM
DBA Dolichos biflorus agglutinin
DIG digoxigenin
DSA Datura stramonium agglutinin
FIU fluorescence intensity unit
Gal galactose
GalNAc N-acetyl galactosamine
GLC gas–liquid chromatography
GlcNAc N-acetyl glucosamine
GNA Galanthus nivalis agglutinin
HA hemagglutination
H2DCFDA 29,79-dichlorofluorescein diacetate
HPA Helix pomatia agglutinin
LPA Limulus polyphemus agglutinin
MAA Maackia amurensis agglutinin
Neu5Ac sialic acid
NHL non-Hodgkin’s lymphoma
9-OAcSa 9-O-acetylated sialic acid
9-OAcSGs 9-O-acetylated sialoglycoconjugates
PNA peanut agglutinin
ROS reactive oxygen species
SNA Sambucus nigra agglutinin
SpA Staphylococcal protein A
SpG Streptococcal protein G
TBS Tris-buffered saline
UEA Ulex europaeus agglutinin
WGA wheat germ agglutinin
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